Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Bastola, 2018, Emerging cancer therapeutic targets in protein homeostasis, AAPS J., 20, 94, 10.1208/s12248-018-0254-1 Miklos, 2001, Protein functions and biological contexts, Proteomics, 1, 169, 10.1002/1615-9861(200102)1:2<169::AID-PROT169>3.0.CO;2-C Santos, 2017, A comprehensive map of molecular drug targets, Nat. Rev. Drug Discov., 16, 19, 10.1038/nrd.2016.230 Powers, 2009, Biological and chemical approaches to diseases of proteostasis deficiency, Annu. Rev. Biochem., 78, 959, 10.1146/annurev.biochem.052308.114844 Chau, 2019, Antibody–drug conjugates for cancer, Lancet, 394, 793, 10.1016/S0140-6736(19)31774-X Wolska-Washer, 2019, Safety and tolerability of antibody-drug conjugates in cancer, Drug Saf., 42, 295, 10.1007/s40264-018-0775-7 Coats, 2019, Antibody–drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index, Clin. Cancer Res., 25, 5441, 10.1158/1078-0432.CCR-19-0272 Roskoski, 2019, Properties of FDA-approved small molecule protein kinase inhibitors, Pharmacol. Res., 144, 19, 10.1016/j.phrs.2019.03.006 Roskoski, 2020, Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update, Pharmacol. Res., 152, 104609, 10.1016/j.phrs.2019.104609 Ohashi, 2013, Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease, J. Clin. Oncol., 31, 1070, 10.1200/JCO.2012.43.3912 Ferguson, 2018, Kinase inhibitors: the road ahead, Nat. Rev. Drug Discov., 17, 353, 10.1038/nrd.2018.21 Fischer, 2017, Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview, Med. Res. Rev., 37, 314, 10.1002/med.21409 Harmsen, 2012, Kinase inhibitor conjugates, Curr. Pharm. Des., 18, 2891, 10.2174/138161212800672778 Finan, 2017, The druggable genome and support for target identification and validation in drug development, Sci. Transl. Med., 9, eaag1166, 10.1126/scitranslmed.aag1166 Fellmann, 2017, Cornerstones of CRISPR–Cas in drug discovery and therapy, Nat. Rev. Drug Discov., 16, 89, 10.1038/nrd.2016.238 Ghosh, 2017, Gene suppression approaches to neurodegeneration, Alzheimer's Res. Ther., 9, 82, 10.1186/s13195-017-0307-1 Wittrup, 2015, Knocking down disease: a progress report on siRNA therapeutics, Nat. Rev. Genet., 16, 543, 10.1038/nrg3978 Burslem, 2020, Proteolysis-targeting chimeras as therapeutics and tools for biological discovery, Cell, 181, 102, 10.1016/j.cell.2019.11.031 Wang, 2020, Degradation of proteins by PROTACs and other strategies, Acta Pharm. Sin. B, 10, 207, 10.1016/j.apsb.2019.08.001 Takahashi, 2020, Targeting selective autophagy by AUTAC degraders, Autophagy, 16, 765, 10.1080/15548627.2020.1718362 Banik, 2020, Lysosome-targeting chimaeras for degradation of extracellular proteins, Nature, 584, 291, 10.1038/s41586-020-2545-9 Cotton, 2021, Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1, J. Am. Chem. Soc., 143, 593, 10.1021/jacs.0c10008 Neklesa, 2011, Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins, Nat. Chem. Biol., 7, 538, 10.1038/nchembio.597 Samarasinghe, 2021, Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras, Cell Chem. Biol., 28, 648, 10.1016/j.chembiol.2021.03.011 Chen, 2016, The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapy, Cancer Lett., 379, 245, 10.1016/j.canlet.2015.06.023 Nandi, 2006, The ubiquitin-proteasome system, J. Biosci., 31, 137, 10.1007/BF02705243 Dikic, 2017, Proteasomal and autophagic degradation systems, Annu. Rev. Biochem., 86, 193, 10.1146/annurev-biochem-061516-044908 Hershko, 1998, The ubiquitin system, Annu. Rev. Biochem., 67, 425, 10.1146/annurev.biochem.67.1.425 Pohl, 2019, Cellular quality control by the ubiquitin-proteasome system and autophagy, Science, 366, 818, 10.1126/science.aax3769 Gu, 2018, PROTACs: an emerging targeting technique for protein degradation in drug discovery, Bioessays, 40, 1700247, 10.1002/bies.201700247 Livneh, 2016, The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death, Cell Res., 26, 869, 10.1038/cr.2016.86 Dong, 2021, Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation, J. Med. Chem., 64, 8884, 10.1021/acs.jmedchem.1c00629 Khan, 2020, Proteolysis targeting chimeras (PROTACs) as emerging anticancer therapeutics, Oncogene, 39, 4909, 10.1038/s41388-020-1336-y Li, 2020, Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy, J. Hematol. Oncol., 13, 50, 10.1186/s13045-020-00885-3 Kregel, 2020, Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment, Neoplasia, 22, 111, 10.1016/j.neo.2019.12.003 Sun, 2019, Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas, Leukemia, 33, 2105, 10.1038/s41375-019-0440-x Jiang, 2019, Development of dual and selective degraders of cyclin-dependent kinases 4 and 6, Angew. Chem. Int. Ed. Engl., 58, 6321, 10.1002/anie.201901336 Li, 2020, Development and characterization of a Wee1 kinase degrader, Cell Chem. Biol., 27, 57, 10.1016/j.chembiol.2019.10.013 Gao, 2020, Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs, ACS Med. Chem. Lett., 11, 1855, 10.1021/acsmedchemlett.9b00372 Popow, 2019, Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions, J. Med. Chem., 62, 2508, 10.1021/acs.jmedchem.8b01826 Gadd, 2017, Structural basis of PROTAC cooperative recognition for selective protein degradation, Nat. Chem. Biol., 13, 514, 10.1038/nchembio.2329 Li, 2022, PROTACs: past, present and future, Chem. Soc. Rev., 51, 5214, 10.1039/D2CS00193D Nowak, 2018, Plasticity in binding confers selectivity in ligand-induced protein degradation, Nat. Chem. Biol., 14, 706, 10.1038/s41589-018-0055-y Farnaby, 2019, BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design, Nat. Chem. Biol., 15, 672, 10.1038/s41589-019-0294-6 Sakamoto, 2001, Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation, Proc. Natl. Acad. Sci. USA, 98, 8554, 10.1073/pnas.141230798 Schneekloth, 2004, Chemical genetic control of protein levels: selective in vivo targeted degradation, J. Am. Chem. Soc., 126, 3748, 10.1021/ja039025z Itoh, 2010, Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins, J. Am. Chem. Soc., 132, 5820, 10.1021/ja100691p Schneekloth, 2008, Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorg. Med. Chem. Lett., 18, 5904, 10.1016/j.bmcl.2008.07.114 Testa, 2018, 3-Fluoro-4-hydroxyprolines: synthesis, conformational analysis, and stereoselective recognition by the VHL E3 ubiquitin ligase for targeted protein degradation, J. Am. Chem. Soc., 140, 9299, 10.1021/jacs.8b05807 Winter Georg, 2015, Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 348, 1376, 10.1126/science.aab1433 Gao, 2020, FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice, Protein Cell, 11, 534, 10.1007/s13238-020-00732-8 Shen, 2020, Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders, J. Med. Chem., 63, 9977, 10.1021/acs.jmedchem.0c01111 Bond, 2020, Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs, ACS Cent. Sci., 6, 1367, 10.1021/acscentsci.0c00411 Zeng, 2020, Exploring targeted degradation strategy for oncogenic KRAS G12C, Cell Chem. Biol., 27, 19, 10.1016/j.chembiol.2019.12.006 Han, 2019, Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer, J. Med. Chem., 62, 941, 10.1021/acs.jmedchem.8b01631 Lee, 2021, Effects of MTX-23, a novel PROTAC of androgen receptor splice variant-7 and androgen receptor, on CRPC resistant to second-line antiandrogen therapy, Mol. Cancer Ther., 20, 490, 10.1158/1535-7163.MCT-20-0417 Lu, 2015, Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4, Chem. Biol., 22, 755, 10.1016/j.chembiol.2015.05.009 Zengerle, 2015, Selective small molecule induced degradation of the BET bromodomain protein BRD4, ACS. Chem. Biol., 10, 1770, 10.1021/acschembio.5b00216 Cao, 2020, Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC), Eur. J. Med. Chem., 208, 112800, 10.1016/j.ejmech.2020.112800 Yang, 2020, Development of selective histone deacetylase 6 (HDAC6) degraders recruiting von Hippel–Lindau (VHL) E3 ubiquitin ligase, ACS. Med. Chem. Lett., 11, 575, 10.1021/acsmedchemlett.0c00046 Gao, 2017, Hydrophobic tagging-mediated degradation of Alzheimer's disease related Tau, RSC Adv., 7, 40362, 10.1039/C7RA05347A de Wispelaere, 2019, Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations, Nat. Commun., 10, 3468, 10.1038/s41467-019-11429-w Zhao, 2021, Discovery of novel BTK PROTACs for B-Cell lymphomas, Eur. J. Med. Chem., 225, 113820, 10.1016/j.ejmech.2021.113820 Du, 2018, Mechanisms of receptor tyrosine kinase activation in cancer, Mol. Cancer, 17, 58, 10.1186/s12943-018-0782-4 Xie, 2021, Development of alectinib-based PROTACs as novel potent degraders of anaplastic lymphoma kinase (ALK), J. Med. Chem., 64, 9120, 10.1021/acs.jmedchem.1c00270 Zhang, 2020, Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC), Eur. J. Med. Chem., 189, 112061, 10.1016/j.ejmech.2020.112061 Burslem, 2018, The advantages of targeted protein degradation over inhibition: an RTK case study, Cell Chem. Biol., 25, 67, 10.1016/j.chembiol.2017.09.009 Zhao, 2020, Discovery of potent small molecule PROTACs targeting mutant EGFR, Eur. J. Med. Chem., 208, 112781, 10.1016/j.ejmech.2020.112781 Zhao, 2022, Discovery of potent PROTACs targeting EGFR mutants through the optimization of covalent EGFR ligands, J. Med. Chem., 65, 4709, 10.1021/acs.jmedchem.1c01827 Shan, 2020, Discovery of novel anti-angiogenesis agents. Part 11: development of PROTACs based on active molecules with potency of promoting vascular normalization, Eur. J. Med. Chem., 205, 112654, 10.1016/j.ejmech.2020.112654 Chen, 2020, Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders, J. Med. Chem., 63, 14562, 10.1021/acs.jmedchem.0c01342 Zhao, 2019, TrkC-targeted kinase inhibitors and PROTACs, Mol. Pharm., 16, 4313, 10.1021/acs.molpharmaceut.9b00673 Siveen, 2018, Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products, Mol. Cancer, 17, 31, 10.1186/s12943-018-0788-y Yang, 2020, Global PROTAC toolbox for degrading BCR–ABL overcomes drug-resistant mutants and adverse effects, J. Med. Chem., 63, 8567, 10.1021/acs.jmedchem.0c00967 Adhikari, 2020, PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase, Nat. Chem. Biol., 16, 1179, 10.1038/s41589-020-00652-y Bozilovic, 2022, Novel, highly potent PROTACs targeting AURORA-A kinase, Curr. Res. Chem. Biol., 2, 100032, 10.1016/j.crchbi.2022.100032 Khan, 2019, A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity, Nat. Med., 25, 1938, 10.1038/s41591-019-0668-z Pal, 2021, Discovery of a novel BCL-XL PROTAC degrader with enhanced BCL-2 inhibition, J. Med. Chem., 64, 14230, 10.1021/acs.jmedchem.1c00517 Shorer Arbel, 2021, Proteolysis targeting chimeras for BTK efficiently inhibit B-cell receptor signaling and can overcome ibrutinib resistance in CLL cells, Front. Oncol., 11, 646971, 10.3389/fonc.2021.646971 Gabizon, 2020, Efficient targeted degradation via reversible and irreversible covalent PROTACs, J. Am. Chem. Soc., 142, 11734, 10.1021/jacs.9b13907 Cromm, 2018, Addressing kinase-independent functions of Fak via PROTAC-mediated degradation, J. Am. Chem. Soc., 140, 17019, 10.1021/jacs.8b08008 Wang, 2020, Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein, J. Med. Chem., 63, 7510, 10.1021/acs.jmedchem.0c00471 Shah, 2020, Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs, Bioorg. Med. Chem., 28, 115326, 10.1016/j.bmc.2020.115326 Alabi, 2021, Mutant-selective degradation by BRAF-targeting PROTACs, Nat. Commun., 12, 920, 10.1038/s41467-021-21159-7 Jiang, 2021, Discovery and resistance mechanism of a selective CDK12 degrader, Nat. Chem. Biol., 17, 675, 10.1038/s41589-021-00765-y Niu, 2022, Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor, Eur. J. Med. Chem., 228, 114012, 10.1016/j.ejmech.2021.114012 Chen, 2021, Design, synthesis, and biological evaluation of IRAK4-targeting PROTACs, ACS Med. Chem. Lett., 12, 82, 10.1021/acsmedchemlett.0c00474 Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858 Wei, 2019, Discovery of a first-in-class mitogen-activated protein kinase kinase 1/2 degrader, J. Med. Chem., 62, 10897, 10.1021/acs.jmedchem.9b01528 Smith, 2019, Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase, Nat. Commun., 10, 131, 10.1038/s41467-018-08027-7 Tovell, 2019, Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader, ACS Chem. Biol., 14, 2024, 10.1021/acschembio.9b00505 Bushweller, 2019, Targeting transcription factors in cancer — from undruggable to reality, Nat. Rev. Cancer, 19, 611, 10.1038/s41568-019-0196-7 Han, 2019, Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands, J. Med. Chem., 62, 11218, 10.1021/acs.jmedchem.9b01393 Itoh, 2011, Design, synthesis and biological evaluation of nuclear receptor-degradation inducers, Bioorg. Med. Chem., 19, 6768, 10.1016/j.bmc.2011.09.041 Zhou, 2019, Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein, J. Med. Chem., 62, 11280, 10.1021/acs.jmedchem.9b01530 Hogg, 2020, Targeting the epigenetic regulation of antitumour immunity, Nat. Rev. Drug Discov., 19, 776, 10.1038/s41573-020-0077-5 Roy, 2019, SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate, ACS Chem. Biol., 14, 361, 10.1021/acschembio.9b00092 Raina, 2016, PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer, Proc. Natl. Acad. Sci. USA, 113, 7124, 10.1073/pnas.1521738113 Chan, 2018, Impact of target warhead and linkage vector on inducing protein degradation: comparison of bromodomain and extra-Terminal (BET) degraders derived from triazolodiazepine (JQ1) and tetrahydroquinoline (I-BET726) BET inhibitor scaffolds, J. Med. Chem., 61, 504, 10.1021/acs.jmedchem.6b01912 Bassi, 2018, Modulating PCAF/GCN5 immune cell function through a PROTAC approach, ACS Chem. Biol., 13, 2862, 10.1021/acschembio.8b00705 Potjewyd, 2020, Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader, Cell Chem. Biol., 27, 47, 10.1016/j.chembiol.2019.11.006 Gao, 2022, Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC), J. Clin. Oncol., 40, 17, 10.1200/JCO.2022.40.6_suppl.017 Flanagan, 2019, Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer, Cancer Res., 79, 10.1158/1538-7445.SABCS18-P5-04-18 Jackson, 2022, Abstract ND09: the discovery and characterization of CFT8634: a potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers, Cancer Res., 82, ND09, 10.1158/1538-7445.AM2022-ND09 Mato, 2022, NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies, Blood, 140, 2329, 10.1182/blood-2022-164772 Cecchini, 2021, From conception to development: investigating PROTACs features for improved cell permeability and successful protein degradation, Front. Chem., 9, 672267, 10.3389/fchem.2021.672267 Anderson, 2020, Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs, Bioorg. Med. Chem. Lett., 30, 127106, 10.1016/j.bmcl.2020.127106 Chamberlain, 2019, Development of targeted protein degradation therapeutics, Nat. Chem. Biol., 15, 937, 10.1038/s41589-019-0362-y Edmondson, 2019, Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: recent progress and future challenges, Bioorg. Med. Chem. Lett., 29, 1555, 10.1016/j.bmcl.2019.04.030 Békés, 2022, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov., 21, 181, 10.1038/s41573-021-00371-6 Li, 2022, Proteolysis-targeting chimeras (PROTACs) in cancer therapy, Mol. Cancer, 21, 99, 10.1186/s12943-021-01434-3 Garber, 2022, The PROTAC gold rush, Nat. Biotechnol., 40, 12, 10.1038/s41587-021-01173-2 Chen, 2022, Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation, Chem. Soc. Rev., 51, 5330, 10.1039/D1CS00762A Lebraud, 2016, Protein degradation by in-cell self-assembly of proteolysis targeting chimeras, ACS Cent. Sci., 2, 927, 10.1021/acscentsci.6b00280 Juan, 2021, Options to improve the action of PROTACs in cancer: development of controlled delivery nanoparticles, Front. Cell Dev. Biol., 9, 805336, 10.3389/fcell.2021.805336 Zoppi, 2019, Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) based dual degrader probe of BRD9 and BRD7, J. Med. Chem., 62, 699, 10.1021/acs.jmedchem.8b01413 Imrie, 2020, Deep generative models for 3D linker design, J. Chem. Inf. Model., 60, 1983, 10.1021/acs.jcim.9b01120 Yang, 2020, SyntaLinker: automatic fragment linking with deep conditional transformer neural networks, Chem. Sci., 11, 8312, 10.1039/D0SC03126G Weng, 2021, PROTAC-DB: an online database of PROTACs, Nucleic Acids Res., 49, D1381, 10.1093/nar/gkaa807 Zheng, 2022, Accelerated rational PROTAC design via deep learning and molecular simulations, Nat. Mach. Intell., 4, 739, 10.1038/s42256-022-00527-y Cao, 2022, Chemistries of bifunctional PROTAC degraders, Chem. Soc. Rev., 51, 7066, 10.1039/D2CS00220E Gooding, 2021, Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma, Blood, 137, 232, 10.1182/blood.2020007081 Sun, 2019, PROTACs: great opportunities for academia and industry, Signal Transduct. Target. Ther., 4, 64, 10.1038/s41392-019-0101-6 Silva, 2019, Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models, Elife, 8, e45457, 10.7554/eLife.45457 Sun, 2018, PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies, Cell Res., 28, 779, 10.1038/s41422-018-0055-1 Zhao, 2019, Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule, Chem. Commun. (Camb.), 55, 369, 10.1039/C8CC07813K Zhang, 2019, Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16, Nat. Chem. Biol., 15, 737, 10.1038/s41589-019-0279-5 Li, 2020, In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15, Signal Transduct. Target. Ther., 5, 129, 10.1038/s41392-020-00245-0 Han, 2017, Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15, Science, 356, eaal3755, 10.1126/science.aal3755 Bussiere, 2020, Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex, Nat. Chem. Biol., 16, 15, 10.1038/s41589-019-0411-6 Ward, 2019, Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications, ACS Chem. Biol., 14, 2430, 10.1021/acschembio.8b01083 Spradlin, 2019, Harnessing the anti-cancer natural product nimbolide for targeted protein degradation, Nat. Chem. Biol., 15, 747, 10.1038/s41589-019-0304-8 Tong, 2020, Bardoxolone conjugation enables targeted protein degradation of BRD4, Sci. Rep., 10, 15543, 10.1038/s41598-020-72491-9 Henning, 2022, Discovery of a covalent FEM1B recruiter for targeted protein degradation applications, J. Am. Chem. Soc., 144, 701, 10.1021/jacs.1c03980 Ohoka, 2019, Development of small molecule chimeras that recruit AhR E3 ligase to target proteins, ACS Chem. Biol., 14, 2822, 10.1021/acschembio.9b00704 Nunes, 2019, Targeting IRAK4 for degradation with PROTACs, ACS Med. Chem. Lett., 10, 1081, 10.1021/acsmedchemlett.9b00219 He, 2021, Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer, Angew. Chem. Int. Ed. Engl., 60, 23299, 10.1002/anie.202107347 Chen, 2021, Folate-guided protein degradation by immunomodulatory imide drug-based molecular glues and proteolysis targeting chimeras, J. Med. Chem., 64, 12273, 10.1021/acs.jmedchem.1c00901 Liu, 2021, Cancer selective target degradation by folate-caged PROTACs, J. Am. Chem. Soc., 143, 7380, 10.1021/jacs.1c00451 Lambert, 2018, Antibody–drug conjugates for cancer treatment, Annu. Rev. Med., 69, 191, 10.1146/annurev-med-061516-121357 Dragovich, 2021, Antibody-mediated delivery of chimeric BRD4 degraders. Part 1: exploration of antibody linker, payload loading, and payload molecular properties, J. Med. Chem., 64, 2534, 10.1021/acs.jmedchem.0c01845 Dragovich, 2021, Antibody-mediated delivery of chimeric BRD4 degraders. Part 2: improvement of in vitro antiproliferation activity and in vivo antitumor efficacy, J. Med. Chem., 64, 2576, 10.1021/acs.jmedchem.0c01846 Pillow, 2020, Antibody conjugation of a chimeric BET degrader enables in vivo activity, ChemMedChem, 15, 17, 10.1002/cmdc.201900497 Hsu, 2020, EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex, Cell Chem. Biol., 27, 41, 10.1016/j.chembiol.2019.11.004 Guenette, 2022, Target and tissue selectivity of PROTAC degraders, Chem. Soc. Rev., 51, 5740, 10.1039/D2CS00200K Bondeson, 2018, Lessons in PROTAC design from selective degradation with a promiscuous warhead, Cell Chem. Biol., 25, 78, 10.1016/j.chembiol.2017.09.010 Cruite, 2022, Cereblon covalent modulation through structure-based design of histidine targeting chemical probes, RSC Chem. Biol., 3, 1105, 10.1039/D2CB00078D Huang, 2018, A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader, Cell Chem. Biol., 25, 88, 10.1016/j.chembiol.2017.10.005 Lai, 2016, Modular PROTAC design for the degradation of oncogenic BCR-ABL, Angew. Chem. Int. Ed. Engl., 55, 807, 10.1002/anie.201507634 Wang, 2021, Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy, Nat. Chem. Biol., 17, 567, 10.1038/s41589-021-00742-5 Steinebach, 2020, Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders, Chem. Sci., 11, 3474, 10.1039/D0SC00167H Xiong, 2021, Chemo-proteomics exploration of HDAC degradability by small molecule degraders, Cell Chem. Biol., 28, 1514, 10.1016/j.chembiol.2021.07.002 Krönke, 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science, 343, 301, 10.1126/science.1244851 Morreale, 2022, BacPROTACs mediate targeted protein degradation in bacteria, Cell, 185, 2338, 10.1016/j.cell.2022.05.009 Marei, 2022, Antibody targeting of E3 ubiquitin ligases for receptor degradation, Nature, 610, 182, 10.1038/s41586-022-05235-6 Costales, 2018, Small molecule targeted recruitment of a nuclease to RNA, J. Am. Chem. Soc., 140, 6741, 10.1021/jacs.8b01233 Costales, 2019, Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA, Cell Chem. Biol., 26, 1180, 10.1016/j.chembiol.2019.04.008 Meyer, 2022, DNA-encoded library screening to inform design of a ribonuclease targeting chimera (RiboTAC), J. Am. Chem. Soc., 144, 21096, 10.1021/jacs.2c07217 Zhang, 2023, Protein phosphatase 5-recruiting chimeras for accelerating apoptosis-signal-regulated kinase 1 dephosphorylation with antiproliferative activity, J. Am. Chem. Soc., 145, 1118, 10.1021/jacs.2c10759 Ghidini, 2021, RNA-PROTACs: degraders of RNA-binding proteins, Angew. Chem. Int. Ed. Engl., 60, 3163, 10.1002/anie.202012330 Shao, 2021, Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O'PROTAC): effective targeting of LEF1 and ERG, Adv. Sci., 8, e2102555, 10.1002/advs.202102555 Liu, 2021, TF-PROTACs enable targeted degradation of transcription factors, J. Am. Chem. Soc., 143, 8902, 10.1021/jacs.1c03852 Samarasinghe, 2022, OligoTRAFTACs: a generalizable method for transcription factor degradation, RSC Chem. Biol., 3, 1144, 10.1039/D2CB00138A Pei, 2022, Targeting key proteins involved in transcriptional regulation for cancer therapy: current strategies and future prospective, Med. Res. Rev., 42, 1607, 10.1002/med.21886 Zhang, 2022, Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin, Mol. Ther. Nucleic Acids, 30, 66, 10.1016/j.omtn.2022.09.008 Hines, 2013, Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs, Proc. Natl. Acad. Sci. USA, 110, 8942, 10.1073/pnas.1217206110 Jin, 2020, Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown, J. Med. Chem., 63, 4644, 10.1021/acs.jmedchem.9b02058 Pfaff, 2019, Reversible spatiotemporal control of induced protein degradation by bistable photoPROTACs, ACS Cent. Sci., 5, 1682, 10.1021/acscentsci.9b00713 Reynders, 2020, PHOTACs enable optical control of protein degradation, Sci. Adv., 6, eaay5064, 10.1126/sciadv.aay5064 Xue, 2019, Light-induced protein degradation with photocaged PROTACs, J. Am. Chem. Soc., 141, 18370, 10.1021/jacs.9b06422 Kounde, 2020, A caged E3 ligase ligand for PROTAC-mediated protein degradation with light, Chem. Commun., 56, 5532, 10.1039/D0CC00523A Naro, 2020, Optical control of small molecule-induced protein degradation, J. Am. Chem. Soc., 142, 2193, 10.1021/jacs.9b12718 Liu, 2020, Light-induced control of protein destruction by opto-PROTAC, Sci. Adv., 6, eaay5154, 10.1126/sciadv.aay5154 Anighoro, 2014, Polypharmacology: challenges and opportunities in drug discovery, J. Med. Chem., 57, 7874, 10.1021/jm5006463 Zheng, 2021, Rational design and synthesis of novel dual PROTACs for simultaneous degradation of EGFR and PARP, J. Med. Chem., 64, 7839, 10.1021/acs.jmedchem.1c00649 Imaide, 2021, Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity, Nat. Chem. Biol., 17, 1157, 10.1038/s41589-021-00878-4 Foley, 2021, Abstract 971: chaperone-mediated protein degradation (CHAMP): a novel technology for tumor-targeted protein degradation, Cancer Res., 81, 971, 10.1158/1538-7445.AM2021-971 He, 2021, Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer, Acta Pharm. Sin. B, 11, 1617, 10.1016/j.apsb.2020.11.022 Steinebach, 2018, Homo-PROTACs for the chemical knockdown of cereblon, ACS Chem. Biol., 13, 2771, 10.1021/acschembio.8b00693 Maniaci, 2017, Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation, Nat. Commun., 8, 830, 10.1038/s41467-017-00954-1 Li, 2007, Degradation of HER2 by Cbl-based chimeric ubiquitin ligases, Cancer Res., 67, 8716, 10.1158/0008-5472.CAN-06-3731 Hatakeyama, 2005, Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation, Cancer Res., 65, 7874, 10.1158/0008-5472.CAN-05-1581 Pan, 2016, A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth, Oncotarget, 7, 44299, 10.18632/oncotarget.9996 Ma, 2013, Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo, Mol. Cancer Ther., 12, 286, 10.1158/1535-7163.MCT-12-0650 Khandia, 2019, A comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: current knowledge and prospects for disease prevention, novel drug design, and therapy, Cells, 8, 674, 10.3390/cells8070674 Ding, 2022, Emerging degrader technologies engaging lysosomal pathways, Chem. Soc. Rev., 51, 8832, 10.1039/D2CS00624C Takahashi, 2019, AUTACs: cargo-specific degraders using selective autophagy, Mol. Cell, 76, 797, 10.1016/j.molcel.2019.09.009 Nedelsky, 2008, Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection, Biochim. Biophys. Acta, 1782, 691, 10.1016/j.bbadis.2008.10.002 Mari, 2010, An Atg9-containing compartment that functions in the early steps of autophagosome biogenesis, J. Cell Biol., 190, 1005, 10.1083/jcb.200912089 Glick, 2010, Autophagy: cellular and molecular mechanisms, J. Pathol., 221, 3, 10.1002/path.2697 Ito, 2013, Endogenous nitrated nucleotide is a key mediator of autophagy and innate defense against bacteria, Mol. Cell, 52, 794, 10.1016/j.molcel.2013.10.024 Li, 2020, ATTEC: a potential new approach to target proteinopathies, Autophagy, 16, 185, 10.1080/15548627.2019.1688556 Li, 2019, Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds, Nature, 575, 203, 10.1038/s41586-019-1722-1 Pei, 2021, Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy, Chem. Commun. (Camb.), 57, 13194, 10.1039/D1CC04661F Dong, 2022, Ispinesib as an effective warhead for the design of autophagosome-tethering chimeras: discovery of potent degraders of nicotinamide phosphoribosyltransferase (NAMPT), J. Med. Chem., 65, 7619, 10.1021/acs.jmedchem.1c02001 Fu, 2021, Degradation of lipid droplets by chimeric autophagy-tethering compounds, Cell Res., 31, 965, 10.1038/s41422-021-00532-7 Ji, 2022, The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system, Nat. Commun., 13, 904, 10.1038/s41467-022-28520-4 Uhlén, 2015, Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419 Spiess, 1990, The asialoglycoprotein receptor: a model for endocytic transport receptors, Biochemistry, 29, 10009, 10.1021/bi00495a001 Ahn, 2021, LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation, Nat. Chem. Biol., 17, 937, 10.1038/s41589-021-00770-1 Zhou, 2021, Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins, ACS Cent. Sci., 7, 499, 10.1021/acscentsci.1c00146 Caianiello, 2021, Bifunctional small molecules that mediate the degradation of extracellular proteins, Nat. Chem. Biol., 17, 947, 10.1038/s41589-021-00851-1 Lai, 2017, Induced protein degradation: an emerging drug discovery paradigm, Nat. Rev. Drug Discov., 16, 101, 10.1038/nrd.2016.211 Neklesa, 2012, Greasy tags for protein removal, Nature, 487, 308, 10.1038/487308a Tae, 2012, Identification of tydrophobic tags for the degradation of stabilized proteins, Chembiochem, 13, 538, 10.1002/cbic.201100793 Long, 2012, Inhibitor mediated protein degradation, Chem. Biol., 19, 629, 10.1016/j.chembiol.2012.04.008 Shi, 2016, Boc3Arg-linked ligands induce degradation by localizing target proteins to the 20S proteasome, ACS Chem. Biol., 11, 3328, 10.1021/acschembio.6b00656 Asawa, 2021, Carborane as an alternative efficient hydrophobic tag for protein degradation, Bioconjug. Chem., 32, 2377, 10.1021/acs.bioconjchem.1c00431 Xie, 2014, Pharmacological targeting of the pseudokinase Her3, Nat. Chem. Biol., 10, 1006, 10.1038/nchembio.1658 Guo, 2022, Hydrophobic tagging-induced degradation of PDEδ in colon cancer cells, ACS Med. Chem. Lett., 13, 298, 10.1021/acsmedchemlett.1c00670 McDonnell, 2015, Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer, J. Med. Chem., 58, 4883, 10.1021/acs.jmedchem.5b00760 Xiang, 2022, Therapeutic strategies to target the androgen receptor, J. Med. Chem., 65, 8772, 10.1021/acs.jmedchem.2c00716 Fischer, 2014, Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide, Nature, 512, 49, 10.1038/nature13527 Lopez-Girona, 2012, Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide, Leukemia, 26, 2326, 10.1038/leu.2012.119 Sievers, 2018, Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN, Science, 362, eaat0572, 10.1126/science.aat0572 Petzold, 2016, Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase, Nature, 532, 127, 10.1038/nature16979 Gemechu, 2018, Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs, Proc. Natl. Acad. Sci. USA, 115, 11802, 10.1073/pnas.1814446115 Kim, 2020, Aryl sulfonamides induce degradation of aryl hydrocarbon receptor nuclear translocator through CRL4DCAF15 E3 ligase, Mol. Cells, 43, 935, 10.14348/molcells.2020.0122 Mayor-Ruiz, 2020, Rational discovery of molecular glue degraders via scalable chemical profiling, Nat. Chem. Biol., 16, 1199, 10.1038/s41589-020-0594-x Słabicki, 2020, The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K, Nature, 585, 293, 10.1038/s41586-020-2374-x Lv, 2020, Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation, Elife, 9, e59994, 10.7554/eLife.59994 Słabicki, 2020, Small-molecule-induced polymerization triggers degradation of BCL6, Nature, 588, 164, 10.1038/s41586-020-2925-1 Simonetta, 2019, Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction, Nat. Commun., 10, 1402, 10.1038/s41467-019-09358-9 Uehara, 2017, Selective degradation of splicing factor CAPERα by anticancer sulfonamides, Nat. Chem. Biol., 13, 675, 10.1038/nchembio.2363 Faust, 2020, Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15, Nat. Chem. Biol., 16, 7, 10.1038/s41589-019-0378-3 Matyskiela, 2018, A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos, J. Med. Chem., 61, 535, 10.1021/acs.jmedchem.6b01921 Bjorklund, 2020, Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN, Leukemia, 34, 1197, 10.1038/s41375-019-0620-8 Yang, 2021, Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently, Cell Res., 31, 1315, 10.1038/s41422-021-00533-6 Schapira, 2019, Targeted protein degradation: expanding the toolbox, Nat. Rev. Drug Discov., 18, 949, 10.1038/s41573-019-0047-y